ArticleInternational journal of women's health2025
IDO-Dependent Tryptophan Metabolites and Endocan as Effective Diagnostic Biomarkers for Pregnancy with Pulmonary Hypertension.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tryptophan metabolism: a potential link between the gut microbiota and pulmonary vascular remodeling in pulmonary hypertension.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pregnancy with pulmonary hypertension (PPH) is one of the main causes of maternal heart failure and death. Endocan is a well-established soluble proteoglycan biomarker for endothelial dysfunction and inflammation. The Indoleamine 2, 3 dioxygenase (IDO) enzyme family comprises IDO1, IDO2, and TDO2, with IDO1-dependent tryptophan metabolites being particularly promising as candidate biomarkers for pulmonary hypertension (PH). However, there have been no reports on the relationship between endocan and IDO1-dependent metabolite and the progression of PPH. The study enrolled 62 patients with PPH and 86 age- and sex-matched healthy people. The concentrations of endocan, B-type natriuretic peptide (BNP), and N-terminal prohormone of BNP (NT-pro BNP) in the serum were detected by enzyme-linked immunosorbent assay. Methods: The Pearson correlation coefficient analyzed the correlation between endocan level and BNP and NT-pro BNP. The concentrations of IDO-dependent tryptophan metabolites in the serum were measured by high-performance liquid chromatography-tandem mass spectrometry. The diagnostic value of endocan and IDO-dependent tryptophan metabolites for PPH was evaluated by the receiver operating characteristic curve (ROC). Results: Results suggested that endocan (PPH vs control: 30.56±3.61 vs 24.53±3.00 ng/mL), BNP (243.40,63.03 vs 98.60,93.35 pg/mL), NT pro-BNP (654.65,363.80 vs 141.70,158.55 pg/mL), kynurenine (1.80±0.23 vs 1.53±0.28 AU), kynurenate (5.17±0.24 vs 4.91±0.27 AU), anthranilate (5.15,2.13 vs 3.00,1.33 AU), and quinolinate (3.62±0.80 vs 2.77±0.81 AU) (all p<0.001) were upregulated in PPH patients. Moreover, Endocan levels showed strong positive correlations with both BNP (r=0.590, p<0.001) and NT pro-BNP (r=0.801, p<0.001). ROC curve showed that the combination of endocan and IDO-dependent tryptophan metabolites had diagnostic value to PPH (AUC: 0.935; 95% CI: 0.896-0.974). Conclusion: In short, we demonstrated that IDO-dependent tryptophan metabolites and endocan could be used as diagnostic biomarkers of PPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.